SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

StockStudio/Compressed
Business
Pfizer CEO: COVID-19 Vaccine Moving at the “Speed of Science,” Not Politics
Pfizer CEO Albert Bourla responds to COVID-19 being brought into this week’s presidential debate with political terms, rather than scientific facts.
October 2, 2020
 · 
2 min read
 · 
Kate Goodwin
Pharm Country
Flame Bioscience to Ignite Pipeline with $100M Common Stock Financing
Proceeds from common stock financing will be used to progress clinical trials for inflammation-driven lung cancer and inflammatory diseases.
September 30, 2020
 · 
2 min read
 · 
Kate Goodwin
Business
Merck KGaA Diversifies with First Female CEO
The German company announced that the new CEO will take the reins in May 2021.
September 29, 2020
 · 
2 min read
 · 
Kate Goodwin
Business
Investors Prove Confidence in InventisBio with $147 Million
Starting with just $11 million seed in 2015, investors have proven their faith in InvestiBio with their increasing financial support.
September 28, 2020
 · 
3 min read
 · 
Kate Goodwin
Policy
Lower Drug Prices: Paper Promise or Actual Change?
During his 2016 campaign, President Trump railed against high pharmaceutical prices, making promises to stand up for Americans who were being “slaughtered” on drug pricing. Now, the FDA has issued a final regulation intended to fulfill Trump’s promises.
September 25, 2020
 · 
3 min read
 · 
Kate Goodwin
Deals
Taysha Makes Rapid Ascent from Launch to IPO
Starting with $30 million in seed financing in April, Taysha sprinted through a $95 million Series B in August and rounded the corner this Thursday to bring in $157 million for its IPO.
September 24, 2020
 · 
2 min read
 · 
Kate Goodwin
Biotech Beach
‘New Kid on the Block’ Libra Raises $29 Million to Tackle Neurodegenerative Diseases
CEO Isaac Veinbergs has big hopes for the company’s unique approach to take on neurodegeneration through cellular cleaning.
September 23, 2020
 · 
3 min read
 · 
Kate Goodwin
Policy
Legend Biotech Names Interim CEO Amid Investigation by Chinese Government
Legend’s CEO and Board Chairman, Fangliang “Frank” Zhange, was placed on “residential surveillance” by PRC law enforcement.
September 21, 2020
 · 
3 min read
 · 
Kate Goodwin
Pharm Country
Researchers Aim to Put Breast Cancer on ‘Lockdown’
Yibin Kang, a professor of molecular biology at Princeton University, and his team have set out to make a world where breast cancer cannot easily spread.
September 19, 2020
 · 
3 min read
 · 
Kate Goodwin
Interest in LAVA’s Potential to Revolutionize Cancer Treatment Evident in $83 Million Series C
LAVA Therapeutics is now financially poised to advance their bispecific antibodies to engage Vγ9Vδ2 T cells in the fight against cancer thanks to an infusion of capital from an oversubscribed $83 million Series C financing.
September 18, 2020
 · 
2 min read
 · 
Kate Goodwin
Load More